Role of urotensin II in health and disease.
Urotensin II (UII) is an 11 amino acid cyclic peptide originally isolated from the goby fish. The amino acid sequence of UII is exceptionally conserved across most vertebrate taxa, sharing structural similarity to somatostatin. UII binds to a class of G protein-coupled receptor known as GPR14 or the urotensin receptor (UT). UII and its receptor, UT, are widely expressed throughout the cardiovascular, pulmonary, central nervous, renal, and metabolic systems. UII is generally agreed to be the most potent endogenous vasoconstrictor discovered to date. Its physiological mechanisms are similar in some ways to other potent mediators, such as endothelin-1. For example, both compounds elicit a strong vascular smooth muscle-dependent vasoconstriction via Ca(2+) release. UII also exerts a wide range of actions in other systems, such as proliferation of vascular smooth muscle cells, fibroblasts, and cancer cells. It also 1) enhances foam cell formation, chemotaxis of inflammatory cells, and inotropic and hypertrophic effects on heart muscle; 2) inhibits insulin release, modulates glomerular filtration, and release of catecholamines; and 3) may help regulate food intake and the sleep cycle. Elevated plasma levels of UII and increased levels of UII and UT expression have been demonstrated in numerous diseased conditions, including hypertension, atherosclerosis, heart failure, pulmonary hypertension, diabetes, renal failure, and the metabolic syndrome. Indeed, some of these reports suggest that UII is a marker of disease activity. As such, the UT receptor is emerging as a promising target for therapeutic intervention. Here, a concise review is given on the vast physiologic and pathologic roles of UII.
Ross
Bryan
B
McGill University Health Center, Montreal, Quebec, Canada
McKendy
Katherine
K
Giaid
Adel
A
D000818:Animals; D019898:Autocrine Communication / Q000502:physiology; D002318:Cardiovascular Diseases / Q000503:physiopathology*; D006801:Humans; D007674:Kidney Diseases / Q000503:physiopathology; D024821:Metabolic Syndrome / Q000503:physiopathology; D019899:Paracrine Communication / Q000502:physiology; D014579:Urotensins / Q000502:physiology*; D014661:Vasoconstriction / Q000502:physiology*
D014579:Urotensins; C029677:urotensin II